^
Association details:
| Biomarker: | Chr del(17p) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Xpovio (selinexor) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)
Published date:
11/04/2021
Excerpt:
ATG-010 (80mg) plus dexamethasone (20mg) was administered twice weekly....Efficacy of Sd was generally consistent across cytogenetic risk subgroups, including del (17p) pts with ORR 22.2% (95% CI: 6.4, 47.6), mDOR 3.8mo, and mPFS 2.9 mo….The MARCH study demonstrates statistically significant and clinically meaningful ORR with Sd in Chinese RRMM pts...
Secondary therapy:
dexamethasone
DOI:
https://doi.org/10.1182/blood-2021-145282
